New FDA-approved SGLT2 Inhibitor Bexagliflozin for Type 2 Diabetes Therapy
DISCOVERIES REPORTS (ISSN 2393249X), 2023, volume 6


FULL text (PDF)

GO BACK to 2023, VOLUME 6

CITATION: Dindere ME. New FDA-approved SGLT2 Inhibitor Bexagliflozin for Type 2 Diabetes Therapy. Discoveries Reports 2023; e40. DOI: 10.15190/drep.2023.4

New FDA-approved SGLT2 Inhibitor Bexagliflozin for Type 2 Diabetes Therapy

Mihaela Elisabeta Dindere 1,2,3 *

1 Ludwig Maximilians University, Munich, Germany 

2 Victor Babes National Institute of Pathology, Bucharest, Romania 

3 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

* Corresponding authors:

Mihaela Elisabeta Dindere, Victor Babes National Institute of Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest Romania: Email:


Type 2 diabetes mellitus (T2DM) is an escalating global challenge, standing out as a prominent public health concern with profound implications for healthcare costs. Recent data reveals the prevalence of diabetes in adults reaching approximately 537 million in 2021, expected to rise to 643 million by 2030. Moreover, it adversely impacts functional capabilities of patients, leading to extensive morbidity and premature mortality. Between 2000 and 2019, age-standardized mortality rates for diabetes increased by 3%, attributed to alarming unhealthy lifestyles, heightened body mass indexes, and health complications due to elevated glycemia, and raising an absolute need for effective treatment approaches. Over the last decade, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have gained popularity as primary medications for T2DM. A noteworthy addition to this class of drugs is TheracosBio’s Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor introduced in January 2023. Thus, phase 3 studies demonstrated bexagliflozin’s efficacy in significantly reducing hemoglobin A1c and fasting blood sugar levels over 24 weeks. As a well-tolerated medication, bexagliflozin exhibits positive effects even in T2DM patients with major adverse cardiovascular events and impaired renal function. Its potential to enhance the overall functionality and life quality of affected individuals, while mitigating the financial burden associated with diabetes care, positions bexagliflozin as a promising advancement in the management of type 2 diabetes mellitus.

Access FULL text of the manuscript here: FULL ARTICLE (PDF)


1. Cooppan R. Rationale and Goals for Glucose Control in Diabetes Mellitus and Glucose Monitoring. Type 2 Diabetes Princ Pract Second Ed. 2016;10:27–44.
2. Webber S. International Diabetes Federation. Vol. 102, Diabetes Research and Clinical Practice. 2013. 147–148 p.
3. Halvorsen RE, Elvestad M, Molin M, Aune D. Fruit and vegetable consumption and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of prospective studies. BMJ Nutr Prev Heal. 2021;4(2):519–31.
4. Moradi S, Kermani MAH, Bagheri R, Mohammadi H, Jayedi A, Lane MM, et al. Ultra-processed food consumption and adult diabetes risk: A systematic review and dose-response meta-analysis. Nutrients. 2021;13(12):1–13.
5. Park JH, Moon JH, Kim HJ, Kong MH, Oh YH. Sedentary Lifestyle: Overview of Updated Evidence of Potential Health Risks. Korean J Fam Med. 2020;41(6):365–73.
6. World Health Organization. Diabetes. [cited 2023 Dec 30]. Available from:
7. Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010;375(9733):2215–22.
8. WebMD Editorial Contributors. Type 2 Diabetes: Symptoms, Causes, Treatment. WebMD. [cited 2023 Dec 30]. Available from:
9. About Diabetes. American Diabetes Association. [cited 2023 Dec 30]. Available from:
10. FDA Approves Brenzavvy. [cited 2023 Dec 30]. Available from:
11. Dholariya S, Dutta S, Singh R, Parchwani D, Sonagra A, Kaliya M. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Opin Pharmacother. 2023;00(00):1–12.
12. Bexagliflozin (Brenzavvy): Advancing Diabetes Management With SGLT-2 Inhibition. [cited 2023 Dec 30]. Available from:
13. Brenzavvy Prescribing Information. [cited 2023 Dec 30]. Available from:
14. Halvorsen YC, McMurray JJV, Freeman MW, Massoro J, Solomon S, Lock P, Riddle MC, Lewis E. The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial. Diabetes. 2020;69(Supplement_1):32-OR.
15. Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328–37.
16. TheracosBio Announces Commercial Availability of BrenzavvyTM (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes . BusinessWire. [cited 2023 Dec 30]. Available from:
17. TheracosBio Announces Publication of Data on the Safety and Effectiveness of BrenzavvyTM (bexagliflozin) as an Adjunct to Metformin. BioSpace. [cited 2023 Dec 30]. Available from:
18. Bexagliflozin. MedScape. [cited 2023 Dec 30]. Available from: